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Background: Investigate the tumor diameter and density changes in advanced melanoma patients treated with
ipilimumab plus bevacizumab, compare response rates based on different response criteria, and study association
between these measures and survival.
Methods: Twenty-one advanced melanoma patients with 59 measurable lesions treated in a phase 1 trial of
ipilimumab plus bevacizumab were retrospectively studied. Tumor diameter and density were measured on
baseline and first follow-up CT. Responses were assigned using RECIST, MASS and Choi criteria. Diameter and
density measures and responses by these criteria were studied for the association with survival.
Results: Twenty-three (39%) lesions and 7 (33%) patients met the Choi density criteria for response (≥15% density
decrease) at the first follow-up. The response rates were 14% (3/21, 95% CI: 3-36%) by RECIST and MASS, and 52%
(11/21, 95% CI: 30-74%) by Choi criteria, when both size and density criteria were used. Larger baseline tumor
diameter was significantly associated with shorter progression-free survival (PFS) and overall survival (OS) (log-rank
p = 0.001 and 0.003; respectively). Diameter or density changes, or responses by RECIST, MASS or Choi criteria at the
first follow-up, were not associated with PFS or OS.
Conclusion: Tumor density decrease meeting Choi criteria was noted in one-third of advanced melanoma patients
at the first follow-up scan during ipilimumab plus bevacizumab therapy. While larger baseline tumor diameter was
strongly associated with shorter survival, changes of diameter or density, or responses by three criteria did not
predict survival. The role of density changes in evaluating response during ipilimumab and bevacizumab therapy
for advanced melanoma remains to be further established.
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Recent advances in the understanding of the mecha-
nisms of tumor immunomodulation and the clinical ap-
plication of immunotherapeutic agents have brought a
new era of cancer immunotherapy [1,2]. Clinical benefit
of immunotherapeutic agents is best demonstrated in
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unless otherwise stated.CTLA-4 antibody, has shown significant improvement
in overall survival (OS) [3]. Ipilimumab has shown clin-
ical activity in other solid tumors such as lung cancer
and prostate cancer [4-6]. Newer agents, including anti-
PD-1 (programmed cell death protein 1) antibodies and
anti-PD-L1 (programmed cell death protein ligand-1)
antibodies, have also shown marked activity against mel-
anoma and other advanced cancers [7-10], further
expanding the role of cancer immunotherapy.
In efforts to further enhance the efficacy of these agents
that block immune checkpoint, predictive markers of re-
sponse to immunotherapy are being actively investigated.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may restrict the anti-tumor activity of cancer treatment,
which may be further enhanced by the abnormal tumor
vasculature [11]. Vascular endothelial growth factor
(VEGF) is a potent angiogenic factor that regulates
angiogenesis and at the same time increases prolifera-
tion, migration, and metastasis of melanoma. VEGF is
also known to inhibit dendritic cell maturation and
T-cell responses [12,13], thus suppressing antitumor
immune responses. Serum level of VEGF-A prior to
treatment was shown to be associated with clinical re-
sponse and OS in advanced melanoma patients treated
with ipilimumab which confirmed a generalizable mech-
anism to immunotherapy resistance via angiogenic cyto-
kines including VEGF [14]. There was no correlation
between changes in VEGF levels following treatment and
clinical outcome [14]. The finding led to the phase 1 study
of the combination therapy of ipilimumab and bevacizu-
mab (anti-angiogenic agent which inhibits VEGF-A). The
trial demonstrated a disease-control rate (defined as the
proportion of patients with best response of complete re-
sponse, partial response, or stable disease at any time
while on study) of 67.4%. The median survival of this
phase 1 study was 25.1 months, which was longer com-
pared to 10.1 months in advanced melanoma patients
treated with ipilimumab alone in a prior phase 3 study [3],
providing a basis for further pursuit of the combination of
immunotherapy and anti-angiogenic therapy [15].
Tumors treated with immunotherapeutic agents are
known to demonstrate unique response patterns on im-
aging, because these agents exert anti-cancer activity by
blocking intrinsic immune inhibition by cancer and causing
T cell infiltration of the tumors [1-3]. These immune-
related response patterns may not be captured by conven-
tional tumor response criteria, such as RECIST and WHO
criteria [16,17]. Immune-related response criteria (irRC)
have been proposed to better describe treatment results of
immunotherapy, and the efforts have been made to further
optimize the methods for immune-related response assess-
ment [18,19].
Tumors treated with anti-angiogenic therapy may
benefit from incorporation of tumor density change on
computed tomography (CT) measured in Hounsfield
Unit (HU), as a marker for devascularization and necro-
sis in response to therapy [20-22]. Furthermore, diam-
eter changes smaller than the conventional threshold
may represent response in these patients. Choi criteria
defined response as ≥10% diameter decrease or ≥15%
decrease in density in patients with gastrointestinal stro-
mal tumors treated with imatinib, which correlate with
disease-specific survival [20-22]. In 40 GIST patients
treated with imatinib, 32 patients met the Choi response
criteria of either a more than 10% decrease in maximum
diameter or a more than 15% decrease in tumor densityat 2 months after treatment, and these 32 patients had
significantly longer time to tumor progression compared
to the remaining 8 patients without Choi response [22].
Choi criteria have been used in renal cell carcinomas
(RCC) and hepatomas treated with sunitinib that blocks
multiple receptor tyrosine kinases including VEGF re-
ceptors [23,24]. Among 26 advanced HCC patients, 17
patients (65.4%) were responders by Choi criteria and
had a significantly longer TTP (7.5 months) compared
with nonresponders (4.8 months; HR = 0.33, P = 0.0182).
In RCC treated with anti-angiogenic therapy, another
modified criteria called MASS (morphology, attenuation,
size, and structure) criteria has been proposed, and de-
fine response as ≥20% diameter decrease, or ≥40HU
density decrease, or marked central necrosis in predom-
inantly solid enhancing lesion(s) [16,25]. MASS criteria
were recently studied in metastatic melanoma treated
with bevacizumab with or without interferon, and shown
to strongly predict progression-free survival (PFS) and
OS [26]. Given these prior observations and the recent
promising phase 1 trial results, it is worthwhile to study
tumor diameter and density changes, in addition to con-
ventional tumor diameter changes, during the combined
therapy of ipilimumab and bevacizumab in capturing
tumor response and predicting outcome.
The purpose of the study is to investigate the tumor
diameter and density changes on CT in advanced melan-
oma patients treated with ipilimumab plus bevacizumab,
compare response rates at the first follow-up based on
different response criteria incorporating tumor diame-
ters and density, and study association between these
measures and survival.
Results and discussion
A total of 59 measurable lesions in 21 patients (median
and mean number of lesions per patient: 2 and 2.8, re-
spectively; range: 1–8) were included. Table 1 summa-
rizes demographics and disease characteristics of the 21
patients. There were 15 lung lesions, 14 peritoneal or
retroperitoneal lesions, 11 liver, 9 subcutaneous, 5 nodes
and 5 adrenal lesions.
Lesion-based analysis
The median baseline diameter and density for the 59
lesions were 25 mm (range: 10–55) and 44.9 HU (range:
7.2-80.1). The median changes at the first follow-up were
10.7% (range: −64.7 to 102.6) for diameter, and −9.7%
(range: -56.6 to 177.2) and −2.7HU (range: -31.0 to 28.3)
for CT density. Figure 1 demonstrates the percent changes
of diameter and density in 59 lesions. Table 2 summarizes
the response by diameter and density of these lesions.
No lesions met the density criteria by MASS, while 23
(39%) lesions met the Choi density criteria (≥15% density
decrease). When diameter and density changes were
Table 1 Summary of patient characteristics and tumor
measurements
Baseline demographics and disease characteristics
Gender Male 14 (66.7)
Female 7 (33.3)
Age (years) Median [Range] 53 [25–68]
Tumor stage IV 20 (95.2)
III Unresectable 1 (4.8)












Baseline sum diameter (mm) Median [Range] 38 [10–178]
Mean [SD] 55.1 [43.9]
Baseline average density (HU) Median [Range] 43.2 [8.0-69.2]
Mean [SD] 43.4 [16.2]
Changes from the baseline measurements
Absolute diameter change at
1st follow-up (mm)
Median [Range] 0 [−21.0 – 56]
Mean [SD] 5.5 [18.0]
Proportional diameter change
at 1st follow-up (%)
Median [Range] 0 [−64.7 – 85.7]
Mean [SD] 3.6 [34.4]
Absolute density change at
1st follow-up (HU)
Median [Range] −4.3 [−24.3 – 18.5]
Mean [SD] −3.1 [10.8]
Proportional density change
at 1st follow-up (%)
Median [Range] −8.4 [−44.3 – 49.1]
Mean [SD] −3.1 [24.5]
The numbers represent the number of patients with percentage in
parentheses, unless otherwise specified.
Ipi = ipilimumab, Bev = bevacizumab.
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(15%) responded by MASS, and 29 lesions (49%)
responded by Choi criteria.
Patient-based analysis
The baseline sum diameter and average density and their
changes on the first follow-up scans are summarized
in Table 1. Figure 2 demonstrates the percent changes
of diameter and density in 21 patients. No patients
met the density criteria by MASS, while 7 (33%, [95%
CI: 15-57%]) patients met density response criteria by
Choi (Table 3). When diameter and density changes are
combined, 3 patients (14%, [95% CI: 3-36%]) responded
by RECIST and MASS, and additional 8 patients
responded by Choi criteria, resulting in a total of 11 Choi
responders (52%, [95% CI: 30-74%]) (Figure 3). None of
the patients with response by these criteria developed new
lesions at the time of the first follow-up scan. In 2 out of13 patients with 2 or more lesions, discrepant CT density
changes among lesions of the same patient was noted,
with some lesions showing >15% density decrease and
other lesions showing marked (i.e., >30%) increase in
density. Both patients met the response by Choi density
criteria when the average density was used to represent
the overall change.
Association with survival
At the time of analysis, 14 patients (67%) had progressed
and 6 patients (29%) had died. The median follow-up
was 29.7 months.
Baseline diameter/density vs. survival
Baseline diameter was significantly associated with PFS
and OS, with larger baseline diameters having poorer
outcomes. When patients were dichotomized at the me-
dian baseline diameter, which was 38 mm in this cohort,
median PFS for patients with baseline diameter ≤38 mm
was 27.5 months compared with 4.1 months for those
with diameter >38 mm (HR (high vs. low) 5.3, [95% CI
1.6 to 18], p = 0.007). Each 5 mm increase in baseline
diameter increased the hazard of a PFS event by 14%
(HR: 1.14, [95% CI 1.05-1.23], p = 0.001) (Figure 4). Median
OS was not reached for patients with diameter ≤38 mm vs.
12.6 months for those with diameter >38 mm. No deaths
occurred in patients with baseline diameters at or below
the median. Each 5 mm increase in baseline diameter in-
crease the hazard of death by 18% (HR= 1.18, [95% CI:
1.06-1.31], p = 0.003) (Figure 5).
Baseline density was not associated with PFS (HR
(high vs. low) 1.3, [95% CI 0.4 to 3.6], p = 0.68) or with
OS (HR (high vs. low) 0.7, 95% CI 0.1 to 4.0, p = 0.71).
Diameter/density changes on the 1st follow-up and outcome
Among the total of 21 patients, 5 patients had pro-
gressed at the 1st follow-up scan while 16 patients had
not progressed. These 16 patients were assessed using a
conditional landmark analysis at 11 weeks (the median
time to the first scan in this group: 11.3 weeks; range:
11–12 weeks). The continuous Cox model, although
limited by the small number of patients (N = 16), sug-
gested that the percent increase of tumor diameter on
the 1st follow-up scan result in shorter PFS and OS.
Each 5% increase in diameter results in a 13% increase
in the hazard of a subsequent PFS event (HR = 1.13,
[95% CI: 0.94-1.36], p = 0.18). Each 1% increase in per-
cent change in diameter increased the risk of death 1.5
times (HR = 1.49, [95% CI: 0.8-3.0], p = 0.25). Neither the
percent nor absolute change in CT density influenced
subsequent PFS (HR for each 5% density increase: 0.997
[95% CI: 0.88-1.14], p = 0.96; HR for each 1 HU density
increase: 0.999 [95% CI: 0.94-1.06], p = 0.98) or OS (HR
for each 5% density increase:1.08 [95% CI: 0.82-1.44],





RECIST (≥30% decrease) 4 (7%)
MASS (≥20% decrease) 9 (15%)
Choi (≥10% decrease) 13 (22%)
Density changes
MASS (≥40HU decrease or marked central necrosis) 0 (0%)
Choi (≥15% decrease) 23 (39%)
Combined diameter and density criteria
MASS (≥20% diameter decrease, ≥40HU
density decrease, or marked central necrosis)
9 (15%)
Choi ((≥10% diameter decrease of ≥15%
density decrease)
29 (49%)
Figure 1 Scatter plot of the percent changes of the tumor diameter and density on the first follow-up CT compared to the baseline CT
in 59 lesions. The cut-off values for response are indicated by the yellow dashed line for RECIST (≥30% diameter decrease), by the orange
dashed line for MASS (≥20% diameter decrease), and by the purple dashed lines for Choi (≥10% diameter decrease or ≥15% density decrease)
criteria. No lesions met the density response criteria by MASS.
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CI: 0.91-1.22], p = 0.51).
Response by RECIST, MASS and Choi criteria vs survival
RECIST and MASS criteria yielded the same 3 re-
sponders and were summarized together. No signifi-
cant PFS or OS differences were observed between
RECIST/MASS responders vs. non-responders (p =
0.45, 0.46, respectively). There was no significant PFS
or OS difference between Choi responders vs. non-
responders (p = 0.90, 0.94, respectively).
Measurement variability
The intra-observer agreement was high for both diam-
eter and density measurements, with CCC of 0.9865 and
0.9967, respectively. The 95% limits of agreement were
(−22.5, 15.5%) for the sum diameter, and were (−5.8,
Figure 2 Scatter plot of the percent changes of the tumor diameter and density on the first follow-up CT compared to the baseline CT
in 21 patients. The cut-off values for response are indicated by the yellow dashed line for RECIST (≥30% diameter decrease), by the orange
dashed line for MASS (≥20% diameter decrease), and by the purple dashed lines for Choi (≥10% diameter decrease or ≥15% density decrease)
criteria. No patients met the density response criteria by MASS.
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Figure 6A-B). The inter-observer agreement was high
for both diameter and density measurements, with CCC
of 0.9774 and 0.9934, respectively. The 95% limits of
agreement were (−27.1, 26.7%) for the sum diameter,
and were (−12.0, 8.3%) and (−4.1, 2.8HU) for the average
density (Table 4, Figure 6C-D).Table 3 The number of patients meeting each response
criteria
Criteria Number of patients
(% [95% CI])
Diameter changes
RECIST (≥30% decrease) 3 (14% [3-36%])
MASS (≥20% decrease) 3 (14% [3-36%])
Choi (≥10% decrease) 6 (28% [11-52%])
Density changes
MASS (≥40HU decrease or marked
central necrosis)
0 (0%)
Choi (≥15% decrease) 7 (33% [15-57%])
Combined diameter and density criteria
MASS (≥20% diameter decrease, ≥40HU
density decrease, or marked central necrosis)
3 (14% [3-36%])
Choi (≥10% diameter decrease of ≥15%
density decrease)
11 (52% [30-74%])Discussion
The present study demonstrated that ≥15% tumor dens-
ity decrease by Choi criteria was noted in one third of
the advanced melanoma patients treated with ipilimu-
mab plus bevacizumab combination therapy at their first
follow-up CT. Larger baseline diameter was strongly as-
sociated with shorter PFS and OS, however, diameter
and density changes or responses by RECIST, MASS, or
Choi criteria at the first follow-up were not associatedFigure 3 A 61-year-old male with metastatic melanoma.
Contrast-enhanced CT scan of the chest at baseline (A) demonstrate
a lobulated right lower lobe mass measuring 37 mm and 54.3 HU
(A, arrow). The follow-up scan (B) at 11.4 weeks of ipilimumab and
bevacizumab therapy demonstrated the lesion measuring 36 mm
and 44.4 HU (B, arrow). While the percent decrease of diameter
was only 2%, CT density decreased by 18% comparing to baseline,
meeting the Choi response criteria.
Figure 4 Progression-free survival in patients dichotomized using the median baseline diameter (38 mm).
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mon phenomenon in advanced melanoma treated with
ipilimumab plus bevacizumab, further studies are needed
to define its role in assessing anti-cancer activity and
therapeutic benefit of the agents and to identify objective
imaging marker that can predict outcome during the
combined immunotherapy and anti-angiogenic therapy.
The degree of diameter and density changes in our co-
hort were similar to the previous report by Gray et al. inFigure 5 Overall survival in patients dichotomized using the mediantheir study of metastatic melanoma patients treated with
bevacizumab with or without interferon, which reported
the average of 2% diameter change and −7% density
change [26]. No lesions or patients in our study met the
density response criteria by MASS, indicating that such
a marked decrease in density is a rare phenomenon
among melanoma patients receiving ipilimumab plus
bevacizumab. Our observation is similar with the report
by Gary et al., which had only 1 out of 118 lesions showingbaseline diameter (38 mm).
Figure 6 Intra- and inter-observer variability of diameter and density measurements. Bland-Altman plots demonstrate the variability of
density and diameter measurements (A, B for intra-observer, C, D for inter-observer, respectively). The relative difference (%) in two independent
measurements for each patient is plotted against the first measurement by Radiologist 1. The straight lines represent the mean relative difference
(%), and the dotted lines represent the upper and lower 95% limits of agreement (%).
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were more frequent in their cohort (6/118 lesions (5%)
and 6/44 patients (14%)), which could be due to the differ-
ent therapeutic regimen in the prior report where the ma-
jority (39/44, 89%) of the patients received interferon in
addition to bevacizumab [26].
When three different criteria for response were used
for 59 lesions, the lesion-based response rate was 7% (4/
59) by RECIST, 15% (9/59) by MASS, and 49% (29/59)
by Choi criteria. For the patient-based analysis, the re-
sponse rate was 14% (3/21) by RECIST and MASS, and
52% (11/21) by Choi (4 patients responding by diameter
decrease, 5 patients by density decrease and 2 patients
meeting both diameter and density criteria). The in-
crease in response rate by applying the Choi density
criteria indicates that CT density decrease may be a se-
quela of the anti-cancer activity of ipilimumab and beva-
cizumab therapy. Similar increase of response rate was
noted in the prior study, in which response rates at thefirst follow-up CT were 7% (3/44) for RECIST, 14% (6/44)
for MASS, and 34% (15/44) for Choi criteria [26].
Heterogeneous changes of CT density within same pa-
tient were noted in 15% (2/13) among the patients with
more than 1 lesion, while overall assessment using the
average density met Choi density response criteria in
both patients. Tumoral heterogeneity is an important
issue in assessing response to targeted therapy [27,28],
and the quantitative imaging approach to address this
issue remain to be established. The current standard ap-
proach including the one used in the present study relies
on a certain number of representative lesions to demon-
strate systemic tumor burden changes, which is associated
with inherent limitations. Further studies are needed to as-
sess the frequency and impact of heterogeneous density
changes during therapy.
While different definitions of response can give rise to
different rates of response, these modified definitions of
response need to be validated by studying association
Table 4 Intra- and inter-observer variability of
measurements in 21 patients
Intra-observer variability




Diameter 0.9865 [0.9691 - 0.9941] −3.5 (%) −22.5, 15.5 (%)
CT density 0.9967 [0.9921 - 0.9987] 0.3 (%) −5.8, 6.5 (%)
0.2 (HU) −2.3, 2.7 (HU)
Inter-observer variability
Diameter 0.9774 [0.9459 - 0.9907] −0.2 (%) −27.1, 26.7 (%)
CT density 0.9934 [0.9841 - 0.9973] −1.9 (%) −12.0, 8.3 (%)
−0.6 (HU) −4.1, 2.8 (HU)
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ical significance if they can differentiate responders with
survival benefit more accurately than the conventional
definitions. In our study, baseline diameter was the only
significant predictor of PFS and OS; other measures in-
cluding baseline density and diameter/density changes at
the first follow-up were not significantly associated with
survival. Univariate Cox models suggested that the
percent increase of tumor diameter on the 1st follow-
up scan may result in shorter PFS and OS; however,
these results need to be viewed cautiously given the
small number of patients and events. None of the
three response criteria (RECIST, MASS and Choi cri-
teria) differentiated patients with longer survival at the
first follow-up scan, indicating the need to further
studies to identify objective markers that can predict
survival at the early course of therapy to guide thera-
peutic decisions. Given the unique mechanism of anti-
cancer activity of ipilimumab, the density changes in the
present cohort may be at least in part due to infiltration of
tumor by immune cells. Future investigations may also
focus on the biological background of the density changes,
as well as the comparison of tumor density among cohorts
receiving ipilimumab alone, bevacizumab alone and the
combination.
Tumor density changes have been extensively studied
in the context of anti-angiogenic therapy to improve
strategy for tumor response evaluation [20,21,23,25].
Recently, immune-related responses have been investi-
gated based on tumor size changes [17-19,29]. The
present study represents the first attempt to further
optimize the existing tumor response criteria specific-
ally for combined therapy using anti-angiogenic agents
and immunomodulating agents, which will be more fre-
quently used in treatment of advanced cancer in the
near future.
Gary et al. reported that MASS response at the first
follow-up strongly predicted PFS and OS [26]. The
different results between 2 studies may be due to thedifferent regimen. Our study also had only 3 MASS
responders. High baseline serum lactate dehydrogen-
ase (LDH) level was also associated with survival in
their study [26]. In our cohort, stratification accord-
ing to elevated baseline LDH was not possible since
there were only 2 patients with elevated levels. The
association between baseline measures and survival
was not mentioned in the prior study [26].
Our study demonstrated high intra- and inter-
observer agreement for both diameter and density
measurements. Based on the 95% limits of agreement,
15% density decrease was beyond the intra- and inter-
observer measurement variability in our cohort. How-
ever, 10% diameter decrease was within the 95% limits
of intra- and inter-observer agreement, alerting the
possibility of misclassification by measurement error
when applying Choi criteria [30]. Intra-observer vari-
ability was narrower than inter-observer variability for
both diameter and density, indicating the measure-
ments by same reader on baseline and follow-up scans
help to decrease misclassification. Given nearly two
thirds of Choi responders (7/11, 64%) responded by
density criteria regardless of the diameter changes, it
may worthwhile to see if adding the density criteria to
the conventional RECIST diameter criteria (≥30% de-
crease) may better identify patients with therapeutic
benefit while avoiding misclassification.
The limitations of the present study include retro-
spective design and a small number of patients treated
at a single institution. Due to the design of the phase 1
trial, the doses of ipilimumab and bevacizumab varied
among the patients in the small cohort. The study re-
ports the initial observations of tumor diameter and
density changes during ipilimumab and bevacizumab
therapy, which needs to be studied further in larger
cohorts. The study also focused on the tumor changes
at the first follow-up study; the role of serial measure-
ments of diameter and density in defining progression
and treatment failure remain to be investigated. The
serial CT density measurements may also help to
identify cases with delayed response to immunother-
apy. In addition, the serial measurements will provide
an opportunity to assess the impact of immune-related
response assessment incorporating new lesions into
the measurements in comparison with the conven-
tional RECIST based approach in the assessment of
CT tumor density.
Conclusions
In conclusion, tumor density decrease meeting Choi criteria
(≥15 % decrease) was relatively common during ipilimumab
plus bevacizumab combination therapy for advanced mel-
anoma, noted in one-third of the patients. Larger baseline
tumor diameter was strongly associated with shorter
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follow-up or responses by RECIST, MASS or Choi criteria
were not associated with survival in these patients. The role
of density changes in evaluating anti-cancer activity and
therapeutic benefit of these agents remain to be further
studied in a larger cohort.Methods
Patients
The study included 21 advanced melanoma patients (14
males, 7 females; median age: 53 years, age range: 25–
68) treated in a phase 1 trial of ipilimumab plus bevaci-
zumab at the Dana-Farber Cancer Institute [15]. All
patients had baseline CT and at least one follow-up CT
using iodinated intravenous contrast agents, and had at
least one measurable lesion (≥10 mm longest diameters
for non-nodal lesions, ≥15 mm in short axis for lymph
nodes [31,32]). Patients were treated with ipilimumab
with four doses at 3-week intervals and then every
12 weeks, and bevacizumab every 3 weeks [15]. The
protocol was approved by the Institutional Review Board
of the Dana-Farber Cancer Institute, and all patients
provided written informed consent. The clinical trial re-
sults including survival and adverse events of the entire
multicenter cohort have been previously reported [15].CT tumor measurements
The standard clinical protocol for body CT at the Dana-
Farber Cancer Institute used a 64-row MDCT scanner
(Aquilion 64; Toshiba America Medical Systems, CA).
Patients are scanned in the supine position from the cra-
nial to caudal direction from the clavicles to the pubic
symphysis at end-inspiration. During the study, 100 mL
of iopromid (Ultravist 300, 300 mg iodine/mL; Bayer
HealthCare Pharmaceuticals Inc. Wayne, NJ) is injected
intravenously at a rate of 3 mL/sec, with a scan delay of
30 seconds for chest and 70 seconds for abdomen (por-
tal venous phase). Axial images (5 mm thickness) were
reconstructed and transferred to a Picture ArchivingTable 5 Summary of tumor response assessment and definitio
RECIST M
Measurements and lesion evaluations Diameter*1 D
C
M
Response criteria*3 ≥30% diameter decrease ≥
o
*1: The longest diameters for non-nodal lesions and short axis for nodes were used
and MASS criteria in the present study.
*2: Marked central necrosis is defined as >50% of the enhancing central portion of
attenuation (necrosis) after treatment [25].
*3: The sum of the diameters of all target lesions and the average of CT density me
follow-up scan during therapy in reference to the values on the baseline pretherapCommunication System (PACS) workstation (Centricity,
General Electric, Milwaukee,WI).
Baseline CT scans prior to initiation of therapy (me-
dian time between baseline scan and initiation of ther-
apy: 1.0 week; range: 0.3-3.0 weeks) were retrospectively
reviewed by a board-certified radiologist with expertise
in oncologic imaging (M.N.). All measurable lesions in
each patient were selected, regardless of the number
of lesions in total or per organ, in order to evaluate het-
erogeneity among lesions within the same patient [28].
The exception included 2 patients with innumerable (>20)
lesions in one organ (lung in one patient and liver in
other), in whom the largest 5 lesions within the organ
(lung/liver) were selected, in addition to all the measurable
lesions in other organs.
The diameters (mm; the longest diameters for non-nodal
lesions and short axis for nodes) and density (HU) were
measured for all lesions on contrast-enhanced CT images
on baseline scans and on the first follow-up scans (median
time to the first follow-up scan: 11.3 weeks). Diameters
were measured using a caliper-type measurement tool on
PACS workstation [33]. The CT attenuation was measured
using an oval region of interest covering the maximum area
of each lesion excluding the surrounding structures [34].
Three lesions (2 lung and 1 subcutaneous lesions) demon-
strated <0 HU at baseline due to partial volume effects,
which were ineligible for the study and excluded.Diameter and density changes on follow-up
The percent changes of diameter and CT density were
calculated on the follow-up scan in reference to the
baseline [35,36]. For CT density, the absolute change
(HU) was also calculated. For lesion-based analysis, the
diameter and density measurements of each lesion were
used. For patient-based analysis, the sum of the diame-
ters and the average of CT density were used to repre-
sent baseline and follow-up measurements [20-22,36];
for those who had >5 lesions in total and >2 lesions per
organ, up to 5 largest lesions in total and up to 2 largestns for RECIST, Choi and MASS criteria
ASS Choi
iameter Diameter
T attenuation (HU) CT attenuation (HU)
arked central necrosis*2
20% diameter decrease, ≥40HU decrease,
r marked central necrosis
≥10% diameter decrease,
or ≥15% density decrease
according to RECIST1.1 [31]. This was applied to size measurement for Choi
a predominantly solid enhancing mass subjectively changing to near fluid
asured in HU are used to assess response, comparing the values on the
y scan.
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based on the baseline measurements.
Response was assigned for each lesion and each pa-
tient, based on RECIST (≥30% decrease in diameter)
[31,32,37], MASS (≥20% decrease in diameter or ≥40HU
decrease in density or marked central necrosis) [25,38]
and Choi criteria (≥10% decrease in diameter or ≥15%
decrease in density) [20-22] (Table 5).
Measurement variability
To assess measurement variability, two board-certified
radiologists (Radiologist 1: M.N. and Radiologist 2:
N.H.R.) independently measured the diameter and
density of all lesions on baseline scans, without access
to other radiologist’s measurements, as described
previously [18,19,36,39]. Radiologist 1 performed mea-
surements twice with one week interval, without access
to the prior measurements.
Statistical analysis
Descriptive methods were used to summarize patient
demographic and disease characteristics. Measurements
on a continuous scale were summarized using mean,
median, standard deviation, and range. Categorical char-
acteristics were summarized using percentages and 95%
exact binomial confidence intervals. The distributions of
progression-free survival (PFS) and overall survival (OS)
were assessed using the product-limit method of Kaplan–
Meier, with 95% confidence intervals (CI) estimated using
log [−log (outcome)] methodology. To investigate the as-
sociation between baseline diameter/density and outcome,
PFS and OS were compared between 2 groups dichoto-
mized at the median baseline diameter (38 mm) or density
(43.2 HU). Cox proportional hazards models were used to
estimate hazard ratios (HRs) and 95% confidence intervals;
p-values are based on the Wald chi-squared statistic. In
addition, univariate Cox proportional hazard models were
used to estimate the effects on outcome of 5 mm incre-
ments in baseline diameter or 5 HU increments in base-
line density. Eleven-week conditional landmark analyses
were used to evaluate differences in outcome according to
response or changes in diameter or density.
All p-values were two-sided, with statistical signifi-
cance defined as P <0.05. There were no corrections for
multiple comparisons.
Intra- and inter-observer variability were assessed using
concordance correlation coefficients (CCCs), mean rela-
tive difference and 95% limits of agreement. CCCs are
products of a measure of precision and a measure of ac-
curacy where CCC value 1 indicates perfect agreement
and −1 indicates perfect reversed agreement [40]. The
mean relative difference (%) between the two measure-
ments is defined as 100*[M1-M2]/M1 (M1 =measurement
1, M2 =measurement 2). Bland-Altman plots were used tovisually demonstrate the variability between the two mea-
surements [36,39,41]. Two measurements of Radiologist
1 were used to assess intra-observer variability. The first
measurement of Radiologist 1 and the measurement
by Radiologist 2 were used to evaluate inter-observer
variability.
Both survival and measurement variability were assessed
according to patient-based analyses, using the sum diame-
ters and the average density for each patient.
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